The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial.
 
Hildur Helgadottir
No Relationships to Disclose
 
Mariaelena Capone
No Relationships to Disclose
 
Claudia Piccinini
No Relationships to Disclose
 
Luisa Piccin
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Novartis; Pierre Fabre; Sun Pharma
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Genesis Pharma; Medison; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Virginia Ferraresi
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Serb
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Novartis; PharmaMar; Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre
 
Ana Arance
Consulting or Advisory Role - Almirall; Biontech; BMS GmbH & Co. KG; Genmab; MSD; Pierre Fabre
Speakers' Bureau - BMS; MSD; Pierre Fabre
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - MSD; Pierre Fabre
 
Michele Guida
Consulting or Advisory Role - Bristol Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
 
Evaristo Maiello
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Novartis; Pfizer; SERVIER
Travel, Accommodations, Expenses - Merck Serono
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; Genesis Pharmaceuticals; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Replimune (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD; Pfizer; Sanofi
 
Pietro Quaglino
Consulting or Advisory Role - Bristol Myers Squibb Foundation; MSD Oncology; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol Myers Squibb Foundation; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Celeste Lebbe
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Inflax; Merck Serono; MSD; Novartis; Pierre Fabre; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Other Relationship - BMS; InflaRx; Jazz Pharmaceuticals; MSD; Novartis; Pierre Fabre; Sanofi
 
Francesco Spagnolo
Honoraria - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Regeneron
Travel, Accommodations, Expenses - Pierre Fabre
 
Maria Vitale
No Relationships to Disclose
 
Ignacio Melero
Honoraria - Flagship Pioneering; PharmaMar
Consulting or Advisory Role - Abbvie; Alligator Bioscience; Amunix; AstraZeneca/MedImmune; BiolineRx; Bright Peak Therapeutics; Bristol-Myers Squibb; Catalym; Curon Biopharmaceutical; Dompé farmaceutici; EMD Serono; F-star; Genmab; Genmab; GlaxoSmithKline; Highlight Therapeutics; Hookipa Pharma; ImmuneSensor Therapeutics; Light Chain Bioscience; Merus; Mestag Therapeutics; Moderna Therapeutics; Monopteros Therapeutics; MSD; Noxxon Pharma; Numab; Pieris Pharmaceuticals; QBiotics; Roche/Genentech; Sanofi; SERVIER; Shattuck Labs
Research Funding - Alligator Bioscience; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche/Genentech
 
Mattias Bergqvist
Employment - Biovica
Patents, Royalties, Other Intellectual Property - Utility of the liquid biomarker thymidine kinase activity for predicting and evaluating Immune Checkpoint Inhibitor efficacy: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023209181 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2 (Inst)
 
Diana Giannarelli
Consulting or Advisory Role - Amgen; Sanofi
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Giuseppe Palmieri
Travel, Accommodations, Expenses - Novartis; Pierre Fabre
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; Immunocore; Italfarmaco; Lunaphore Technologies; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre; Replimune